乙基3-碘-4-甲基苯甲酸酯 | 859212-59-2

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 芳香烃
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 乙基3-碘-4-甲基苯甲酸酯
• 英文名称: 3-iodo-4-methyl-benzoic acid ethyl ester
• 英文别名: ethyl-3-iodo-4-methyl benzoate；ethyl 3-iodo-4-methylbenzoate；3-Jod-4-methyl-benzoesaeure-aethylester
• CAS: 859212-59-2
• 化学式: C₁₀H₁₁IO₂
• 分子量: 290.101
• InChiKey: KMIVUJKEQAPRIH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  乙基3-碘-4-甲基苯甲酸酯 在 copper(l) iodide 、 tris(dibenzylideneacetone)dipalladium (0) 、 tetratrifurylphosphinepalladium 哌啶 、 4-氯苯酚钾 、 对氯苯酚 、 三苯基膦 作用下， 以 N,N-二甲基甲酰胺-d7 为溶剂， 反应 1.0h， 生成 Ethyl 3-[2-(5-ethoxycarbonyl-2-methylphenyl)ethynyl]-4-methylbenzoate
  参考文献：
  名称：

  Solid-Phase Synthesis of m-Phenylene Ethynylene Heterosequence Oligomers

  摘要：

  Both homo- and heterosequence m-phenylene ethynylene oligomers are synthesized using a conceptually simple iterative solid-phase strategy. Oligomers are attached to Merrifield's resin through a known triazene-type linkage. The phenylene ethynylene molecular backbone is constructed through a series of palladium-mediated cross-coupling reactions. The strategy employs two types of monomers that bear orthogonal reactivity, one being a monoprotected bisethynyl arene and the other being a 3-bromo-5-iodo arene. The catalyst conditions are tailored to the requirements of each monomer type. The monoprotected bisethynyl arene is coupled to the growing chain in 2 h at room temperature using a Pd(I) dimer precatalyst ((Bu3P)-Bu-t-(Pd(mu-Cl)(mu-2-methyl allyl) Pd)(PBu3)-Bu-t) in conjunction with ZnBr2 and diisopropylamine. In alternate steps, the resin is deprotected in situ with TBAF and coupled to the 3-bromo-5-iodo arene using the iodo selective Pd(tri-2-furylphosphine) 4 catalyst in conjunction with CuI and piperidine; this reaction is also completed in 2 h at room temperature. These cross-coupling events are alternated until an oligomer of the desired length is achieved. The oligomer is then cleaved from the resin using CH2I2/I-2 at 110 degrees C and purified using preparatory GPC. Using this method, a series of homo- and heterosequence oligomers up to 12 units in length in excellent yield and purity were synthesized on the 100 mg scale. Longer oligomers were attempted; however, deletion sequences were found in oligomers longer than 12 units.

  DOI：

  10.1021/jo0607212
• 作为产物：
  描述：

  乙醇 、 3-碘-4-甲基苯甲酸 在 硫酸 作用下， 以88%的产率得到乙基3-碘-4-甲基苯甲酸酯
  参考文献：
  名称：

  Solid-Phase Synthesis of m-Phenylene Ethynylene Heterosequence Oligomers

  摘要：

  Both homo- and heterosequence m-phenylene ethynylene oligomers are synthesized using a conceptually simple iterative solid-phase strategy. Oligomers are attached to Merrifield's resin through a known triazene-type linkage. The phenylene ethynylene molecular backbone is constructed through a series of palladium-mediated cross-coupling reactions. The strategy employs two types of monomers that bear orthogonal reactivity, one being a monoprotected bisethynyl arene and the other being a 3-bromo-5-iodo arene. The catalyst conditions are tailored to the requirements of each monomer type. The monoprotected bisethynyl arene is coupled to the growing chain in 2 h at room temperature using a Pd(I) dimer precatalyst ((Bu3P)-Bu-t-(Pd(mu-Cl)(mu-2-methyl allyl) Pd)(PBu3)-Bu-t) in conjunction with ZnBr2 and diisopropylamine. In alternate steps, the resin is deprotected in situ with TBAF and coupled to the 3-bromo-5-iodo arene using the iodo selective Pd(tri-2-furylphosphine) 4 catalyst in conjunction with CuI and piperidine; this reaction is also completed in 2 h at room temperature. These cross-coupling events are alternated until an oligomer of the desired length is achieved. The oligomer is then cleaved from the resin using CH2I2/I-2 at 110 degrees C and purified using preparatory GPC. Using this method, a series of homo- and heterosequence oligomers up to 12 units in length in excellent yield and purity were synthesized on the 100 mg scale. Longer oligomers were attempted; however, deletion sequences were found in oligomers longer than 12 units.

  DOI：

  10.1021/jo0607212

文献信息

• Preparation of Polyfunctional Indazoles and Heteroarylazo Compounds Using Highly Functionalized Zinc Reagents
  作者：Benjamin Haag、Zhihua Peng、Paul Knochel

  DOI：10.1021/ol901585k

  日期：2009.10.1

  available 2-chloromethylarylzinc reagents react with functionalized aryldiazonium tetrafluoroborates providing polyfunctional indazoles. Selective metalations of these 2-aryl-2H-indazoles afford new polycyclic aromatics. The performance of a chemoselective addition of diheteroarylzincs to aryldiazonium salts allows an efficient preparation of new heterocyclic azo compounds.

  现成的2-氯甲基芳基锌试剂与功能化的四氟硼酸芳基重氮反应，生成多官能的吲唑。这些2-芳基-2 H-吲唑的选择性金属化提供了新的多环芳族化合物。将二杂芳基锌化学选择性加成到芳基重氮盐中的性能允许有效地制备新的杂环偶氮化合物。
• THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES
  申请人：Son Jung Beom

  公开号：US20130053370A1

  公开（公告）日：2013-02-28

  The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.

  本发明涉及一种具有以下化学式（I）的噻吩[3,2-d]嘧啶衍生物，或其药用可接受的盐、水合物或溶剂化合物，该衍生物对蛋白激酶具有优异的抑制活性，包括该衍生物的药物组合物在预防或治疗异常细胞生长性疾病方面具有有效性。
• BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE
  申请人：Jung Seung Hyun

  公开号：US20120302567A1

  公开（公告）日：2012-11-29

  The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.

  本发明涉及一种新颖的双环杂环芳基衍生物，其药用盐，水合物和溶剂合物，具有改进的蛋白激酶抑制活性，并且包括作为活性成分的药物组合物，用于预防或治疗异常细胞生长紊乱。
• PROCESSES FOR MAKING PONATINIB AND INTERMEDIATES THEREOF
  申请人：Apicore US LLC

  公开号：US20160108053A1

  公开（公告）日：2016-04-21

  Novel synthetic approaches to make 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide, intermediates and pharmaceutically acceptable salts thereof are provided.

  本发明提供了制备3-(咪唑[1,2-b]吡嗪-3-基乙炔基)-4-甲基-N-[4-[(4-甲基哌嗪-1-基)甲基]-3-(三氟甲基)苯基]苯甲酰胺、其中间体和药学上可接受的盐的新合成方法。
• Viral Polymerase Inhibitors
  申请人：Beaulieu Pierre Louis

  公开号：US20090087409A1

  公开（公告）日：2009-04-02

  An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: A is O, S, NR 1 , or CR 1 , wherein R 1 is defined herein; represents either a single or a double bond; R 2 is selected from: H, halogen, R 21 , OR 21 , SR 21 , COOR 21 , SO 2 N(R 22 ) 2 , N(R 22 ) 2 , CON(R 22 ) 2 , NR 22 C(O)R 22 or NR 22 C(O)NR 22 wherein R 21 and each R 22 is defined herein; B is NR 3 or CR 3 , with the proviso that one of A or B is either CR 1 or CR 3 , wherein R 3 is defined herein; K is N or CR 4 , wherein R 4 is defined herein; L is N or CR 5 , wherein R 5 has the same definition as R 4 ; M is N or CR 7 , wherein R 7 has the same definition as R 4 ; Y 1 is O or S; Z is N(R 6a )R 6 or OR 6 , wherein R 6a is H or alkyl or NR 61 R 62 wherein R 61 and R 62 are defined herein; and R 6 is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het; or R 6 is wherein R 7 and R 8 and Q are as defined herein; Y 2 is O or S; R 9 is H, (C 1-6 alkyl), (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl, aryl, Het, (C 1-6 )alkyl-aryl or (C 1-6 )alkyl-Het, all of which optionally substituted with R 90 ; or R 9 is covalently bonded to either of R 7 or R 8 to form a 5- or 6-membered heterocycle; a salt or a derivative thereof, as an inhibitor of HCV NS5B polymerase.

  化合物的同分异构体、对映异构体、非对映异构体或互变异构体，由公式I表示：其中：A为O、S、NR1或CR1，其中R1在此定义；表示单键或双键；R2选自：H、卤素、R21、OR21、SR21、COOR21、SO2N（R22）2、N（R22）2、CON（R22）2、NR22C（O）R22或NR22C（O）NR22，其中R21和每个R22在此定义；B为NR3或CR3，但A或B中的一个为CR1或CR3，其中R3在此定义；K为N或CR4，其中R4在此定义；L为N或CR5，其中R5具有与R4相同的定义；M为N或CR7，其中R7具有与R4相同的定义；Y1为O或S；Z为N（R6a）R6或OR6，其中R6a为H或烷基，或NR61R62，其中R61和R62在此定义；R6为H、烷基、环烷基、烯基、Het、烷基-芳基、烷基-Het；或R6为，其中R7、R8和Q在此定义；Y2为O或S；R9为H、（C1-6）烷基、（C3-7）环烷基或（C1-6）烷基-（C3-7）环烷基、芳基、Het、（C1-6）烷基-芳基或（C1-6）烷基-Het，其中所有这些都可以选择地用R90取代；或R9与R7或R8中的任意一个共价键结合形成5-或6-成员杂环；其盐或衍生物，作为HCV NS5B聚合酶的抑制剂。